Actively Recruiting
Open-Label Study of Intravitreal EYC-0305 for Safety in Patients With Neovascular Age-Related Macular Degeneration
Led by Eyconis INC. · Updated on 2026-10-09
30
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of EYC-0305, an extended-delivery anti-VEGF biological drug, in patients aged 50 years and older with neovascular wet age-related macular degeneration AMD. This Phase 1b2a study aims to assess how well patients tolerate the treatment and monitor any side effects. The study will also examine how the drug is processed in the body and its impact on disease activity and vision. Participants will receive intravitreal IVT injections of EYC-0305 every 24 weeks, with multiple ascending dose levels studied sequentially. The study includes four dose levels of EYC-0305 administered to different groups of patients. The treatment period extends up to 72 weeks to evaluate long-term safety and drug effects. Throughout the study, participants will undergo regular assessments including monitoring of ocular and systemic treatment-emergent adverse events up to Week 72. Clinic visits will include ophthalmic imaging and other study-related procedures to evaluate safety and the effect on vision. Participants must consent and commit to compliance with all study visits and procedures during the trial, which is expected to complete by May 2028.
CONDITIONS
Brief Title
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Research Team
K
Kim Reed, OD, FAAO
K
Karen Chu, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here